# Insight into the Hypoglycemic Effects of Pinus nigra Arn. Bark Extracts Through In Silico and In Vivo Analysis

**Authors:** Nemanja Maletin, Nikola Denda, Maja Milanović, Nataša Milić, Nina Pavkov, Aleksandar Rašković, Milica Paut Kusturica

PMC · DOI: 10.3390/plants15030462 · Plants · 2026-02-02

## TL;DR

This study explores how Pinus nigra bark extract may help lower blood sugar and improve metabolic health in diabetic rats.

## Contribution

The study combines in silico and in vivo methods to evaluate the hypoglycemic potential of Pinus nigra bark extract.

## Key findings

- The ethanol extract reduced glycaemia and improved glucose tolerance in diabetic rats.
- Combining the extract with metformin or gliclazide showed additive hypoglycemic effects.
- The extract also favorably modulated dyslipidaemia in treated rats.

## Abstract

Diabetes mellitus is a major global health burden, and plant-derived polyphenols are increasingly explored as adjuncts for metabolic control. Hence, the hypoglycaemic potential of Pinus nigra bark extract from Serbia was evaluated using complementary in silico and in vivo approaches. Major constituents reported for P. nigra bark (catechin, epicatechin, taxifolin, caffeic, ferulic, p-coumaric, protocatechuic, and syringic acids) were docked against selected metabolic targets (LXRα, LXRβ, PTP1B, and SUR1) as hypothesis-generating screening due to the frequent PAINS behaviour of small polyphenols. For in vivo assessment, normoglycaemic and alloxan-induced diabetic Wistar rats received a 7-day oral treatment with ethanol bark extract (100 mg/kg) alone or combined with metformin (100 mg/kg) or gliclazide (10 mg/kg), and fasting glycaemia, oral glucose tolerance, lipid profile, and body weight were assessed. The ethanol extract reduced glycaemia, improved glucose tolerance, and favourably modulated dyslipidaemia, with additive effects observed in combinations with metformin or gliclazide. These findings suggest activity relevant to hypoglycaemic-relevant activity of P. nigra bark extract in vivo; however, comprehensive chemical profiling, mechanistic confirmation, and safety evaluation are required before translational consideration.

## Linked entities

- **Proteins:** NR1H3 (nuclear receptor subfamily 1 group H member 3), NR1H2 (nuclear receptor subfamily 1 group H member 2), PTPN1 (protein tyrosine phosphatase non-receptor type 1), ABCC8 (ATP binding cassette subfamily C member 8)
- **Chemicals:** catechin (PubChem CID 1203), epicatechin (PubChem CID 1203), taxifolin (PubChem CID 471), caffeic acid (PubChem CID 689043), ferulic acid (PubChem CID 445858), p-coumaric acid (PubChem CID 637542), protocatechuic acid (PubChem CID 72), syringic acid (PubChem CID 10742), metformin (PubChem CID 4091), gliclazide (PubChem CID 3475)
- **Diseases:** Diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** Ptpn1 (protein tyrosine phosphatase, non-receptor type 1) [NCBI Gene 24697] {aka Ptp, Ptp1b}, Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 58852] {aka LXRalpha}, Abcc8 (ATP binding cassette subfamily C member 8) [NCBI Gene 25559] {aka Sur, Sur1}
- **Diseases:** Diabetes mellitus (MESH:D003920)
- **Chemicals:** glucose (MESH:D005947), catechin (MESH:D002392), lipid (MESH:D008055), gliclazide (MESH:D005907), P. nigra bark extract (-), metformin (MESH:D008687), polyphenols (MESH:D059808), syringic acids (MESH:C001945), taxifolin (MESH:C003377), ethanol (MESH:D000431), alloxan (MESH:D000496)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12899274/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12899274/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12899274/full.md

---
Source: https://tomesphere.com/paper/PMC12899274